Radiopharm TheranosticsRADX
13F holders, Q2 2026 (June 30)6holders −1
0new positions
1sold out
$0.02avg. 13F price*
At the end of Q2 2026, 6 institutions reported holding Radiopharm Theranostics Ltd. (RADX) in their 13F filings, down 1 from Q1 2026. 0 opened new positions and 1 sold out. The largest holders were Stonepine Capital Management, LLC ($671K), HSBC Holdings PLC ($254K) and Regal Partners Ltd ($168K).
- Company
- Radiopharm Theranostics Ltd.
- CUSIP
- 75041J101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $806K |
All 13F filers, Q1 2026 → Q2 2026: 4,890 shares bought and 188,899 shares sold, net −184,009 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Stonepine Capital Management, LLC | 0.51% | No change | 51,000,000 | $671K |
| HSBC Holdings PLC | 0.00% | Add +1.3% | 62,188 | $254K |
| Regal Partners Ltd | 0.01% | No change | 40,138 | $168K |
| PNC Financial Services Group, Inc. | 0.00% | Add +25.0% | 20,000 | $84K |
| UBS Group AG | 0.00% | Reduce -49.8% | 1,507 | $6K |
| Rhumbline Advisers | 0.00% | Add +61.2% | 195 | $817 |
"% of holder's portfolio" is RADX's weight in each manager's 13F, not the share of Radiopharm Theranostics Ltd. the manager owns.